羟考酮(强阿片)与对乙酰氨基酚可待因复方(弱阿片)用于骨折术后亚急性疼痛的随机临床试验
该双盲、优效性随机临床试验在澳大利亚悉尼一家大型创伤医院开展,纳入因长骨或骨盆、髌骨、跟骨、距骨急性非病理性骨折接受手术固定并出院的住院患者,从出院时开始分别使用羟考酮(5 mg或10 mg,即1或2片)或对乙酰氨基酚与可待因复方(500 mg与8 mg或1000 mg与16 mg,即1或2片),每日4次,最长3周。共随机120例,强阿片组59例、弱阿片组61例。出院后第1至7天,强阿片组每日NRS平均疼痛评分为4.04(95%CI 3.67至4.41),弱阿片组为4.54(95%CI 4.17至4.90),组间差异无统计学意义(-0.50,95%CI -1.11至0.12;P=0.11)。作者结论认为强阿片亚急性期治疗不优于较弱阿片,提示不应支持出院后继续一线使用强阿片。
要点
- 骨折术后出院第1至7天,强阿片组NRS平均疼痛评分4.04(95%CI 3.67至4.41),弱阿片组4.54(95%CI 4.17至4.90),组间差异无统计学意义(-0.50,95%CI -1.11至0.12;P=0.11)。
- 强阿片组第1至7天口服吗啡当量均值为32.9 mg,弱阿片组为5.5 mg,即强阿片组阿片剂量增加约6倍,但疼痛评分差异仍无统计学意义。
- 该双盲、优效性随机临床试验在澳大利亚悉尼一家大型创伤医院单中心开展,随机120例因急性非病理性骨折接受手术固定的住院患者。
- 作者结论认为,骨折术后亚急性期使用强阿片药物不优于较弱药物治疗疼痛,提示不应支持出院后继续一线使用强阿片。
适用人群与场景
- 因长骨或骨盆、髌骨、跟骨、距骨急性非病理性骨折接受手术固定的住院患者,于出院时开始研究干预。
- 研究在澳大利亚悉尼一家大型创伤医院单中心开展,纳入时间为2016年7月27日至2017年8月22日。
处置流程与药物剂量
- 出院时开始羟考酮盐酸盐5 mg或10 mg(即1或2片),每日4次,最长3周。
- 出院时开始对乙酰氨基酚与可待因复方500 mg与8 mg或1000 mg与16 mg(即1或2片),每日4次,最长3周。
- 主要结局为治疗第1周每日疼痛评分均值,采用数字疼痛评定量表(NRS,0至10分,0为无痛,10为可想象的最严重疼痛),患者每日评定过去24小时的平均疼痛。
研究设计与关键结果
- 研究类型:双盲、优效性、随机临床试验,单中心(澳大利亚悉尼一家大型创伤医院),共随机120例,强阿片组59例、弱阿片组61例。
- 人群特征:强阿片组43例(72.9%)男性,平均(SD)年龄36.0(14.1)岁;弱阿片组47例(77.1%)男性,平均(SD)年龄38.2(13.5)岁。
- 药物暴露:强阿片组第1至7天口服吗啡当量均值为32.9 mg,弱阿片组为5.5 mg。
- 主要终点:出院后第1至7天,强阿片组每日NRS平均疼痛评分为4.04(95%CI 3.67至4.41),弱阿片组为4.54(95%CI 4.17至4.90),组间差异无统计学意义(-0.50,95%CI -1.11至0.12;P=0.11),尽管强阿片组阿片剂量增加约6倍。
- 关键次要终点包括EQ-5D-5L问卷、最严重疼痛、药物不良事件、总体感知效果和重返工作。
证据类型、等级与局限
- 证据类型:随机临床试验(双盲、优效性设计)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,骨折术后亚急性期使用强阿片药物不优于较弱药物治疗疼痛,提示不应支持出院后继续一线使用强阿片。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Patients with a surgically managed fracture are commonly discharged from the hospital with a strong opioid prescription, but limited evidence exists to support this practice.
OBJECTIVE: To test the hypothesis that strong opioids provide greater analgesia than mild opioids over the first week postdischarge from hospital after fracture surgical treatment.
DESIGN, SETTING, AND PARTICIPANTS: This double-blind, superiority, randomized clinical trial was conducted at a single-center, major trauma hospital in Sydney, Australia. Participants were inpatients who had sustained an acute nonpathological facture of a long bone or the pelvis, patella, calcaneus, or talus who were treated with surgical fixation and enrolled from July 27, 2016, to August 22, 2017. Data were analyzed from June through October 2018.
INTERVENTIONS: Initiation at discharge of oxycodone hydrochloride 5 mg of 10 mg (ie, 1 or 2 tablets) or combination acetaminophen and codeine 500 mg and 8 mg or 1000 mg and 16 mg (ie, 1 or 2 tablets) 4 times daily for a maximum duration of 3 weeks.
MAIN OUTCOMES AND MEASURES: The primary outcome was the mean of daily pain scores collected during week 1 of treatment measured using the Numerical Pain Rating Scale (NRS). Participants were asked to rate their mean pain over the previous 24 hours daily using an NRS score from 0 to 10, with 0 representing no pain and 10 representing the worst pain imaginable. The key secondary outcomes were EuroQol 5-Dimension 5-Level Questionnaire (EQ-5D-5L) responses, worst pain, medication adverse events, global perceived effect, and return to work.
RESULTS: A total of 120 patients with 1 or more acute orthopedic fractures requiring surgical fixation were randomized, including 59 patients in the strong-opioid group (43 [72.9%] men; mean [SD] age, 36.0 [14.1] years; mean oral morphine equivalent for days 1-7 of 32.9 mg) and 61 patients in the mild opioid group (47 [77.1%] men; mean [SD] age, 38.2 [13.5] years; mean oral morphine equivalent for days 1-7 of 5.5 mg). From days 1 to 7 postdischarge, the mean daily NRS mean pain score was 4.04 (95% Cl, 3.67 to 4.41) in the strong opioid group and 4.54 (95% Cl, 4.17 to 4.90) in the mild opioid group. The between-group difference of the primary outcome was not statistically significant (-0.50 [95% Cl, -1.11 to 0.12]; P = .11) despite a 6-fold increased dose of opioids being delivered in the strong opioid group.
CONCLUSIONS AND RELEVANCE: This study found that treatment with strong opioid medication subacutely was not superior to treatment with milder medication for treatment of pain among patients with surgically managed orthopedic fractures. These findings suggest that ongoing first-line strong opioid use after discharge from the hospital should not be supported.
TRIAL REGISTRATION: Australia New Zealand Clinical Trial Registry No.: ACTRN12616000941460.
参考来源
- Jenkin DE, Naylor JM, Descallar J, et al. Effectiveness of Oxycodone Hydrochloride (Strong Opioid) vs Combination Acetaminophen and Codeine (Mild Opioid) for Subacute Pain After Fractures Managed Surgically: A Randomized Clinical Trial. JAMA Netw Open. 2021. PMID: 34787656. doi:10.1001/jamanetworkopen.2021.34988
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。